COMMUNIQUÉS West-GlobeNewswire

Sanofi : Dupilumab Significantly Reduced Steroid Use, Asthma Attacks, and Improved Lung Function in a Phase 3 Study of People with Severe Steroid-Dependent Asthma

31/10/2017 - 11:58

Press Release Source: Sanofi (EURONEXT: SAN) (NYSE: SNY) Dupilumab Significantly Reduced Steroid Use, Asthma Attacks, and Improved Lung Function in a Phase 3 Study of People with Severe Steroid-Dependent Asthma First [...]

Sanofi : Le dupilumab a permis de réduire significativement le recours aux corticoïdes et les crises d'asthme, et d'améliorer la fonction respiratoire, dans une étude de phase 3 portant sur des pe...

31/10/2017 - 11:58

Communiqué de presse Source : Sanofi (EURONEXT : SAN) (NYSE: SNY) Le dupilumab a permis de réduire significativement le recours aux corticoïdes et les crises d'asthme, et d'améliorer la fonction respiratoire, dans une [...]

Clinical Decision Support System (CDSS) Market Worth $1,500 Million by 2022: Acumen Research and Consulting

31/10/2017 - 11:19

Acumen Research and Consulting, a global provider of market research studies, in a recently published report titled " Clinical Decision Support System Market (Solutions: Integrated CDSS Solutions, Standalone CDSS [...]

Photocure ASA: Presentation of the third quarter 2017 results

31/10/2017 - 11:08

Photocure will present its third quarter report on Wednesday 8 November 2017 at Hotel Continental, Oslo, Norway. The presentation will begin at 08:30 (CET) and representatives from the company will be Kjetil Hestdal, [...]

HOMEVI S.A.S. CONFIRMS DATE OF REDEMPTION OF ITS €608 MILLION 6.875% SENIOR SECURED NOTES DUE 2021 AND ITS €200 MILLION FLOATING RATE SENIOR SECURED NOTES DUE 2021

31/10/2017 - 11:00

Suresnes, October 31, 2017 - 11:00 am CET HomeVi S.A.S. ("HomeVi"), today confirms that it has deposited aggregate proceeds in a sufficient quantity to pay the redemption price for all of its outstanding €608,000,000 6. [...]

NANOBIOTIX leve 27,2 millions d'euros dans le cadre d'un placement d'actions ordinaires nouvelles

31/10/2017 - 08:00

NANOBIOTIX LEVE 27,2 MILLIONS D'EUROS DANS LE CADRE D'UN PLACEMENT D'ACTIONS ORDINAIRES NOUVELLES Les fonds ont été levés par construction accélérée d'un livre d'ordre annoncé le 30 octobre 2017 Paris, France, et [...]

NANOBIOTIX successfully completes approximately eur 27.2 million placement of new shares

31/10/2017 - 08:00

NANOBIOTIX SUCCESSFULLY COMPLETES APPROXIMATELY EUR 27.2 MILLION PLACEMENT OF NEW SHARES Funds raised via an accelerated book building offering announced on October 30, 2017 Paris, France and Cambridge, Massachusetts ( [...]

Verona Pharma to Announce Operational Update and Financial Results for the Third Quarter Ended September 30, 2017

31/10/2017 - 08:00

LONDON, Oct. 31, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for [...]

Immunocore to Present New Overall Survival Data in Metastatic Uveal Melanoma at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting

31/10/2017 - 08:00

PRESS RELEASE Immunocore to Present New Overall Survival Data in Metastatic Uveal Melanoma at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting (Oxford, UK and Conshohocken, US, 31 October 2017) [...]

Verona Pharma to Present at Two Upcoming Investor Conferences

31/10/2017 - 07:55

LONDON, Oct. 31, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for [...]

DBV Technologies Reports September 30, 2017 Cash Position

31/10/2017 - 07:30

Press Release Montrouge, France, October 31, 2017 DBV Technologies Reports September 30, 2017 Cash Position DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT) today announced its cash and [...]

DBV Technologies publie sa position de trésorerie au 30 septembre 2017

31/10/2017 - 07:30

Communiqué de Presse Montrouge, France, le 31 octobre 2017, 7h30 CET DBV Technologies publie sa position de trésorerie au 30 septembre 2017 DBV Technologies, (Euronext: DBV - ISIN : FR0010417345 - NASDAQ : DBVT), [...]

Basilea's Chief Medical Officer Prof. Achim Kaufhold to retire and Dr. Marc Engelhardt named as successor

31/10/2017 - 07:15

Basel, Switzerland, October 31, 2017 - Basilea Pharmaceutica Ltd. (SIX: BSLN) reported today that Prof. Achim Kaufhold will retire after seven years with the company. Basilea named Dr. Marc Engelhardt, currently Basilea [...]

Novartis submits application to FDA for KymriahTM (tisagenlecleucel) in adult patients with r/r DLBCL, seeking second indication for first-ever FDA approved CAR-T therapy

31/10/2017 - 07:15

Media release (PDF) This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for the [...]

Cancellation of publicly held Actelion shares and delisting from SIX Swiss Exchange as of November 7, 2017

31/10/2017 - 07:00

ALLSCHWIL/BASEL, SWITZERLAND - October 31, 2017 - By decision dated October 25, 2017, the Cantonal Court of the Canton of Basel-Landschaft cancelled all publicly held registered shares of Actelion Ltd ( Actelion ) with [...]

TiGenix provides regulatory update on Cx601 EU Marketing Authorization Application procedure

31/10/2017 - 07:00

PRESS RELEASE TiGenix provides regulatory update on Cx601 EU Marketing Authorization Application procedure Leuven (BELGIUM) - October 31, 2017, 7:00h CET - TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced [...]

ABLYNX CLOSES ON UNDERWRITERS' OPTION TO PURCHASE $30 MILLION OF ADDITIONAL SHARES IN THE U.S. INITIAL PUBLIC OFFERING

30/10/2017 - 21:30

REGULATED INFORMATION GHENT, Belgium, 30 October 2017 - Ablynx NV [Euronext Brussels and Nasdaq: ABLX] , a late-stage clinical biopharmaceutical company utilising its proprietary Nanobody® platform to develop treatments [...]

Nightstar Therapeutics to Participate in Multiple Conferences in November

30/10/2017 - 21:05

LEXINGTON, Mass. and LONDON, Oct. 30, 2017 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc (NASDAQ:NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal diseases, today announced [...]

Diaxonhit : Résultats semestriels 2017, Bénéfices très positifs de l'acquisition de Capforce Plus

30/10/2017 - 19:02

DIAXONHIT - Résultats semestriels 2017 Premiers bénéfices très positifs de l'acquisition de Capforce Plus Réussite de la première phase d'intégration Accélération de la dynamique commerciale Objectifs opérationnels [...]